EFFEXOR TABLETS, 75MG

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)

MAH:

WYETH CANADA

ATC_code:

N06AX16

INN:

VENLAFAXINE

dosage:

75MG

pharmaceutical_form:

TABLET

composition:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG

administration_route:

ORAL

units_in_package:

100

prescription_type:

Prescription

therapeutic_area:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

leaflet_short:

Active ingredient group (AIG) number: 0131294001; AHFS:

authorization_status:

CANCELLED POST MARKET

authorization_date:

2004-08-19

SPC

PRODUCT MONOGRAPH
Pr
EFFEXOR
®
(Venlafaxine Hydrochloride)
Tablets
Pr
EFFEXOR
®
XR
(Venlafaxine Hydrochloride)
Extended Release Capsules
ANTIDEPRESSANT/ANXIOLYTIC
WYETH CANADA
DATE OF PREPARATION:
MONTREAL, CANADA
July 18, 1994
Control Number:
DATE OF REVISION:
094122
November 16, 2004
THIS PRODUCT MONOGRAPH IS THE EXCLUSIVE PROPERTY OF WYETH
CANADA AND CANNOT BE REFERENCED, PUBLISHED OR COPIED WITHOUT
THE WRITTEN APPROVAL OF WYETH CANADA.
©Wyeth Canada
2
EFFEXOR/EFFEXOR XR
(Venlafaxine HCl)
PRODUCT MONOGRAPH
TABLE OF CONTENTS
PAGE
ACTIONS AND CLINICAL PHARMACOLOGY . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . 4
INDICATIONS AND CLINICAL USE . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . 16
CONTRAINDICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
18
WARNINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
PRECAUTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Discontinuation Symptoms
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 28
Use in Pregnancy, Labour and Delivery, and in Nursing Mothers
. . . . . . . . . . . . . . . . . 36
Paediatric Use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . 38
Use in the Elderly
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . 38
Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Drug Abuse and Dependence . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . 47
ADVERSE